Aurora Spine stock analysis
Want to see TSE:ASG full AI Analyst Report?
Aurora Spine (ASG) Stock Price & Analysis
ASG Stock Chart & Stats
- Day’s Range
- CAD 0.10 - CAD 0.10
- 52-Week Range
- CAD 0.09 - CAD 0.33
- Previous Close
- CAD 0.09
- Volume
- N/A
- Average Volume (3M)
- 19.31K
- Market Cap
- CAD 7.03M
- Enterprise Value
- CAD 21.95M
- Total Cash (Recent Filing)
- CAD 362.04K
- Total Debt (Recent Filing)
- CAD 2.17M
- Price to Earnings (P/E)
- ―
- Beta
- 0.40
- Next Earnings
- Nov 17, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Operating Scale
Revenue remains materially above 2021 levels, while slightly positive EBITDA in 2025 and 2026 TTM indicates some operating leverage. If maintained, this combination can support a more durable earnings base, although profitability has not yet become consistent.
Positive Cash Generation
Positive operating and free cash flow since 2024 is a meaningful improvement over 2021–2023 and provides internal liquidity for ongoing operations. This cash generation can reduce reliance on external funding, though the latest decline means durability still needs confirmation.
Moderating Leverage
Debt-to-equity fell from about 0.93 in 2025 annual to 0.62 in 2026 TTM, making the capital structure more manageable. Lower leverage improves resilience and preserves financing flexibility as the company works toward consistent profitability.
Bears Say
Persistent Unprofitability
Net losses, negative operating profit and negative net margin persist across every period shown, while ROE remains meaningfully negative. This indicates the business has not yet converted product activity into dependable shareholder returns and may continue eroding its equity cushion.
Recent Revenue Softness
Revenue declined in 2026 TTM versus the prior year after expanding from earlier periods. The reversal weakens current growth momentum and could limit operating leverage, making it harder for Aurora Spine to turn improving gross margin and EBITDA into sustained profits.
Volatile Free Cash Flow
Although free cash flow is positive, it declined sharply in 2026 TTM versus 2025 annual. That volatility weakens confidence in the repeatability of internal cash generation and could constrain funding for future operating needs if the deterioration persists.
Aurora Spine News
ASG FAQ
What was Aurora Spine’s price range in the past 12 months?
What is Aurora Spine’s market cap?
When is Aurora Spine’s upcoming earnings report date?
How were Aurora Spine’s earnings last quarter?
Is Aurora Spine overvalued?
Does Aurora Spine pay dividends?
What is Aurora Spine’s EPS estimate?
How many shares outstanding does Aurora Spine have?
What happened to Aurora Spine’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aurora Spine?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Aurora Spine
Established in 2013 and headquartered in Toronto, Canada, Aurora Spine Corporation, through its subsidiary Aurora Spine, Inc., specializes in the development and distribution of advanced, minimally invasive spinal fusion systems and devices within the Canadian market. The company offers a comprehensive portfolio of products designed to address various spinal conditions, particularly degenerative disc diseases. This includes interspinous process lumbar fusion devices such as the ZIP series (ZIP, ZIP ULTRA, ZIP LP, and ZIP-51). Aurora Spine also provides Ti-Coated polyether ether ketone (PEEK) interbody cages, which are crucial for maintaining space and stability between vertebrae while facilitating bone fusion. Its offerings extend to sterile-packed titanium plasma spray coated spinal fusion implants that promote bone growth. Key interbody products comprise EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar region, and Discovery for cervical applications. The company also manufactures SOLO, an anterior lumbar interbody fusion (ALIF) 3D-printed stand-alone device featuring an integrated plate and spacer system for anatomical preservation and spinal support. For sacroiliac joint issues, Aurora Spine provides SiLo, a posterior fusion device. Furthermore, the DEXA-C cervical interbody system, a porous 3D-printed intervertebral body fusion device with customizable lattice density options, is available to match patient bone quality.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Trent J. Northcutt
- Employees
- 13
- Website
- www.aurora-spine.com
- Address
- 20 Holly Street, Toronto, ON, M4S 3B1, CA
Aurora Spine (ASG) Earnings & Revenues
ASG Earnings Call
Earnings Call SentimentNeutral
The earnings call highlights significant revenue growth, product success, and gross margin improvements. However, these positives are tempered by increased operating expenses, a fourth-quarter EBITDAC decline, and a sustained net loss. While Aurora's product portfolio shows promise, financial challenges remain.
View all TSE:ASG earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 4 | 12 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 2 | 0 | 10 |







